Tag: REDWOOD-HCM OLE

CYTOKINETICS PRESENTS NEW DATA FROM REDWOOD-HCM OLE IN LATE BREAKING CLINICAL TRIAL SESSION AT THE HFSA ANNUAL SCIENTIFIC MEETING

Coronary/Structural Heart by 0 comments

Treatment with Aficamten Associated with Significant Improvements in Symptoms and Quality of Life Additional Data Presented in Poster Session Shows Patients with Worsening Heart Failure and LVEF ≤30% Have Disproportionately High Risk of Heart Failure Hospitalization SOUTH SAN FRANCISCO, Calif., Oct. […]

Continue Reading →

Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HCM Society Scientific Sessions

Coronary/Structural Heart by 0 comments

New Analysis Demonstrates Successful Reduction or Withdrawal of Standard of Care Therapies in Patients Treated with Aficamten SOUTH SAN FRANCISCO, Calif., Sept. 30, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today presented new data on the reduction and withdrawal […]

Continue Reading →